[ad_1] Cantor Fitzgerald initiated coverage on Sorrento Therapeutics Inc (NASDAQ: SRNE) with an Overweight rating and a price target of $5. The analyst…
Read More »[ad_1] Cantor Fitzgerald initiated coverage on Sorrento Therapeutics Inc (NASDAQ: SRNE) with an Overweight rating and a price target of $5. The analyst…
Read More »